Grünenthal GmbH

https://www.grunenthal.com

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn. *

	Start	1946-01-01 established
	Group	Grünenthal (Group)
	Industry	pain drug
	Industry 2	pharmaceutical
	Person	Baertschi, Gabriel (Grünenthal 201610– CEO before President AstraZeneca Japan + Managing Director AstraZeneca GmbH)
	Person 2	Raschke, Fabian (Grünenthal 201902– CFO joined 201609 before Xella Group)

	Region	Aachen
	Country	Germany
	Street	6 Zieglerstr.
	City	52099 Aachen
	Tel	+49-241-569-0
		Address record changed: 2024-01-05

Basic data	Employees	F: 1,001 to 5,000 (2020-12-31)
	Currency	EUR
	Annual sales	1,300,000,000 (revenues, consolidated (2020) 2020-12-31)

		* Document for »About Section«: Grünenthal GmbH. (4/12/21). "Press Release: Grünenthal Acquires Mestex AG and Its Phase-III-ready Investigational Medicine MTX-071 for the Treatment of Pain Associated with Osteoarthritis of the Knee". Aachen.

		Record changed: 2023-12-30